
# Humana Investor Day 2017



# Humana

April 25, 2017

## Humana 2017 Investor Day: Business Session Agenda

Торіс	Presenter	
Welcome	Regina Nethery	
Strategic Overview	Bruce Broussard	
CEO Q&A Session	Bruce Broussard	
Retail	Alan Wheatley	
Provider	Roy Beveridge, MD; Joe Jasser, MD	
Q&A Session	Panel	
Evolving Clinical Model	William Fleming, PharmD; Chris Kay	
Simplified Experience	Jody Bilney; Brian LeClaire, PhD	
Q&A Session	Panel	
Group	Beth Bierbower	
Financial Update	Brian Kane	
Q&A Session	Brian Kane	
Closing Remarks	Bruce Broussard	
Luncheon with Humana Management		

### **Cautionary statement**

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like "expects," "anticipates," "believes, " "intends," "likely will result," "estimates," "projects" or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the "Risk Factors" section of our SEC filings, as listed below.

In making these statements, Humana is not undertaking to address or update these statements in future filings or communications regarding its business or results. In light of these risks, uncertainties and assumptions, the forward-looking events discussed herein might not occur. There also may be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC:

- Form 10-K for the year ended December 31, 2016;
- Form 8-Ks filed during 2017.

# Strategic Overview

**Bruce Broussard** President and Chief Executive Officer



Humana

**Investor Day 2017** 



# **Our Strategy**

We strive to improve the health of **seniors living with chronic conditions** through an **Integrated Care Delivery** model that brings simplicity and connectivity to the healthcare experience

# How we win

By **partnering with providers** to evolve incentives from treating health episodically to **managing health holistically** 

Through building **trusted relationships** with our members and making it easier for them to engage in their health by providing clinical programs that intersect **healthcare and lifestyle** – *helping them at key moments of need* 

By **leveraging technology** to integrate systems and simplify processes so that members and providers may **engage more fully and easily in managing holistic health** 

Provider joint ventures Alliances Owned clinics MSO<sup>1</sup>

Home health Behavioral health Pharmacy Prevention

Advanced analytics Provider-facing workflows Consumer applications to reduce friction points

### Our investment thesis

#### Our competitive advantage

### Leading brand in retail insurance market

- Focused strategy on highest growth segment – seniors living with chronic conditions in Medicare Advantage (MA)
- Proven success in clinical management of multiple products

# Driving deep integration of the healthcare experience to improve health outcomes

- Rich history in provider partnerships and population health
- Proven Healthcare Services business integrated with Insurance Products

# Multiple growth levers ensuring sustained organic growth

#### Proven results in market

2014	2017E	CAGR		
EPS (GAAP)				
\$7.36	\$16.91	+32%		
<b>EPS</b> (Adjusted) <sup>1</sup>				
\$8.29	\$11.10	+10%		
• Consolidated Revenues (GAAP)				
\$48.5B	\$54.0B	+4%		
<b>Consolidated Revenues</b> (Adjusted) <sup>1</sup>				
\$45.5B	\$53.0B	+5%		

Maintained strong performance through period of industry and company uncertainty

1. Represents an Adjusted financial measure that is not in accordance with Generally Accepted Accounting Principles (GAAP). Reconciliations of GAAP to non-GAAP financial measures as well as management's explanation for using such is included at the back of this slide deck.

# Rising healthcare costs are driven by an aging population and growing chronic disease prevalence

# Population with chronic disease is growing...


# of people in U.S. with at least one chronic disease (M)<sup>1</sup>

#### ...especially among Medicare-eligible seniors...

% of people in U.S. with at least one chronic disease, by age group<sup>2</sup>

# ...pressuring sustainability and affordability

US National Health Expenditures (\$T)<sup>3</sup>



# Chronic disease is a primary driver of increasing costs in the US healthcare system

The current health care system is not suited to address the growing need for chronic care management



## Numerous barriers to chronic care management:

- Fee For Service (FFS) payments inherently episodic in nature
- Weak incentive for holistic and preventive care
- Limited quality-based payments

Management of lifestyle activities is not easily integrated with the healthcare delivery system

Siloed nature of industry causes significant complexity for providers and frustration for consumers Maturity of technology is low due to siloed platforms and numerous barriers to implementation

Interoperability of technology is limited due to lack of standardization and misaligned incentives Understanding the members we serve and their experiences with the healthcare system at key moments in their health journeys

**Steven** 





Adjusting to new prescriptions following hospital discharge Juan






Coping with acute and chronic conditions simultaneously Don






Managing health with limited social support

To help members like Steven, Juan, and Don, we are evolving the system from an episodic to holistic health focus




Dis-integrated. Conflicted. Focused on **episodic care**.



### Simple. Personalized. Focused on **holistic health**.

Right care at right time. Convenient access. Face-to-face. Aligned incentives.


Moving beyond treatment to improve health via lifestyle management creates tremendous value




# MA serves the growing senior population with a revenue model to improve outcomes and cost effectiveness

# Seniors increasingly choosing MA for affordability and health management

- Senior population expected to nearly double by 2050<sup>1</sup>
- MA is a holistic solution allowing members to manage their costs better than fee-for-service Medicare
  - Healthcare costs 5x higher with chronic disease, with which vast majority of seniors cope<sup>2</sup>
- Younger seniors are increasingly selecting MA over original Medicare





# Reflects growing senior population, clear value proposition, and shifting consumer preference

#### Humana.

1. Census bureau 2014 2. Centers for Disease Control and Prevention (CDC) 2012 3. Kaiser Family Foundation (KFF) Medicare Private Plan enrollment projection 2016 4. Penetration equals KFF MA enrollment divided by CMS Medicare enrollment projection - 2016 CMS projection from Annual Report to Board of Trustees Our leading Health Plan and Healthcare Service platforms position us to uniquely meet the needs of the MA market

# Health Plans

- Leading Medicare position with 30+ years of Medicare experience and excellent consumer satisfaction
  - 3.3 million MA members<sup>1</sup>; 5.2 million stand-alone
     Prescription Drug Plan (PDP) members<sup>2</sup>
  - 18% total medical membership growth from 2012-2016<sup>3</sup>
  - Ranked #1 national health insurer in consumer experience in 2017 survey<sup>4</sup>
  - Strong brand commitment
     with >38% of seniors positive
     or committed to Humana<sup>5</sup>

# Healthcare Services

- Primary Care and Prevention & Wellness Services<sup>6</sup>
  - ~150 owned and joint venture (JV) clinics
  - 64% of Individual MA members managed by physicians in value-based relationships
  - >99% of MA network adequacy gaps closed
  - 4.9M members in go365 Wellness program
- Humana Pharmacy and Humana At Home
  - 4<sup>th</sup> largest Pharmacy Benefits Manager<sup>7</sup> (PBM); integrated with the clinical model
  - Consistently ranked one of the top mail order pharmacies in customer satisfaction according to JD Power<sup>8</sup>
  - Approximately 1M members engaged in Humana At Home; creates platform for further expansion
- Integrated Clinical & Consumer Analytics platform
  - Advanced analytic models run on all MA members daily
  - Quantifies ~50 dimensions of clinical risk to enable personalized management
  - 2.5B pieces of clinical data analyzed daily though CareHub


Strong organic growth requires a consumer-focused, clinically sound, and cost-effective strategy

# QUALITY MEMBERSHIP GROWTH is driven by...

- Improved clinical outcomes
- Simplified experience
- Productive platform
- Affordable products



Our approach centers on integrating the clinical and lifestyle aspects of health to *proactively* manage major cost drivers



# To realize our strategy, we are investing in our Integrated Care Delivery platform

# **Provider:** Motivating the transition from treatment to health

- Primary care clinics
- MSO

### *Clinical:* Extending provider reach beyond the office – to the moment and place of most effective influence

 Implement through Pharmacy, Behavioral Health, Home Health

# **Experience:** Building trusted relationships to drive engagement

- Remove friction points through improved processes
- Facilitate integration at point of care

### Integrated Care Delivery (ICD) Model



An integrated platform delivered in a local market

# We have built strong Integrated Care Delivery capabilities over the years with demonstrated success



Clinical: Extending provider reach and influence



Experience: Building trust and driving engagement

### Scaled assets<sup>1</sup>

64% of Humana Individual MA members treated by physicians in value-based relationships

~300k members in MSO, owned, alliance and JV practices

#### ~560k members in HCCP<sup>5</sup>

Humana Pharmacy expected to mail over 42M prescriptions in 2017

20k active CareHub (clinical IT platform) users

3.6M members in Wellness program

50% consumer digital self-service rate

11k associates on CRM<sup>8</sup> platform

#### **Positive impact**

- **19%** HEDIS score improvement<sup>2</sup>
- 18% PMPM cost reduction<sup>3</sup>
- ~30% ER VPT reduction<sup>3,4</sup>
- ~10% hospital APT reduction<sup>3,5</sup>
- 87% HCCP clinical engagement
- 44% reduction in APT for HCCP<sup>6</sup>
- 28% higher NPS<sup>7</sup> in Humana Pharmacy
- Rated #1 National health insurer for customer experience<sup>9</sup>
- \$46M saved from member Welcome Experience redesign
- >205k unnecessary transfer and 500k repeat calls avoided

### Given successes, we are ready to accelerate our strategy

Humana

1. All data 2016 or Q1 2017 unless otherwise noted. 2. Healthcare Effectiveness Data Information Set; 2015. 3. For members with VBR providers relative to members with FFS providers. 4. Emergency Room Visits Per Thousand members 5. Admissions Per Thousand members. 6. Humana Chronic Care Program 6. Relative to members not in HCCP 7. Net Promoter Score 8. Customer Relationship Management. 9. Temkin, #2 overall Our integrated strategy is bolstered by a talented workforce of associates strongly committed to our mission

Our strong culture and mission have been

recognized in recent years

Associate retention and engagement have remained high during transaction period<sup>1</sup>





Our health-focused business model coordinated with our purpose has created a motivated organization

# **Our Bold Goal**

The communities we serve will be **20% healthier by 2020** because we make it easy for people to achieve their best health Member Unhealthy Days

decreased by

an average of **3%** in our

**Bold Goal Markets** 

between 2015-2016, and up

to 9% in some markets

## We are committed to sustaining strong growth over the long term

High value integrated care delivery creates a virtuous cycle of growth




Key levers to drive value

- Membership growth
- Growth in Healthcare Services
- Productivity
- Return of capital

Low to mid teens Adjusted EPS growth

## We are led by a cohesive, deeply experienced management team



## Q&A

# Humana

Investor Day 2017

## Retail

Alan Wheatley President, Retail




# Humana

Investor Day 2017

# Humana has delivered solid growth and strategic positioning in the growing Medicare Advantage segment

Humana projects growth in Individual MAPD net membership of ~800K between '13 – '17E, an industry leading growth rate



#### Key success factors for future growth:

- $\checkmark\,$  Innovative products that integrate care and grow membership in key markets
- $\checkmark\,$  Clinical capabilities that improve engagement and outcomes
- $\checkmark$  Local market provider integration to manage population health and provide value based care
- ✓ Diversified distribution model including strategic external relationships
- Strong performance on quality measures
- $\checkmark\,$  Simplified experience that drives acquisition, engagement, and retention


Humana. 1. 2017E is based on the midpoint of guidance for simplicity 2. As of Feb 17. 3. 2016 represents most recent full-year membership data publicly available 4. Average of 3 largest national competitors based on 2016 ending membership: United, Aetna, Anthem.

## Humana's value-based plan philosophy has delivered industry leading Individual PDP membership growth and #1 market share

Humana Individual PDP membership grew over four times faster than competitors from 2013-2016








Business positioning and value proposition:	Key success factors for future growth:
<ul> <li>#1 market share, increasing from 17% in 2013</li> </ul>	<ul> <li>Value-based plan philosophy</li> </ul>
<ul> <li>Market leader in value based plans, with lowest premium in 31 states</li> </ul>	<ul> <li>Increasing mail order usage to improve quality and enhance retention</li> </ul>
<ul> <li>Ability to cross-sell into MA and utilize mail-order pharmacy</li> </ul>	✓ High quality, efficient networks
<ul> <li>Strong external partnerships enhance acquisition and retention efforts</li> </ul>	<ul> <li>Effective management of specialty drug trends</li> <li>Co-branded distribution relationships</li> </ul>

Humana. 1. Excludes Group PDP and LI-NET 2. 2017E is based on the midpoint of guidance for simplicity 3. As of Feb '17 4. 2016 represents most recent full-year membership data publicly available 5. Average of United, CVS, Aetna end 2016 membership

# State-Based Contracts are a high-growth business that generates significant revenue and supports dual-eligible growth

#### 2013-2017 estimated membership growth at 47% CAGR

Humana State-Based Contracts ending membership 2013 – 2017E



Business positioning and value proposition:

- Profitable business grown organically
- Supports D-SNP growth, as an emerging state trend requires a Medicaid presence to enroll Dualeligibles in Special Needs Plans (D-SNP)
- Capabilities benefitting duals can also be utilized within MA business (e.g., expanded communitybased partnerships)

#### Key success factors for future growth:

- Focused growth in states with meaningful dual eligible populations
- Continued investments in integrated, differentiating technology applications and administrative insourcing
- Clinical model supporting expanded membership trends (e.g., severe mental illness)
- Continued focus on administrative cost efficiency
- ✓ Agility to enable timely responses as public policy evolves

## Our integrated care delivery strategy enables quality MA growth

#### We are integrating care delivery...

#### Humana's integrated care delivery strategy:



#### ... across 3 key sets of initiatives...


**Provider integration:** *Deepening and expanding primary care and Humana MSO capabilities* 

**Clinical engagement:** Enhancing home care, behavioral health, and pharmacy capabilities

**Simplified experience:** Improving the member and provider experience and their interactions with Humana

generating quality growth across four key dimensions:				
Provider	Product	Member	Financial	
Increase in value-based providers and membership	Premium and benefit stability	Improvement in member engagement, retention and NPS	Meaningful long-term pre-tax growth	

We are creating a simple and personalized experience to drive engagement with consumers and providers



Member outcomes and experience improvements driven by provider models and supporting capabilities



Clinical and population health capabilities customized to meet member and provider needs			
Select capabilities:			
Humana At Home	<ul> <li>In-home care management</li> <li>Discharge planning solutions</li> </ul>		
Humana Pharmacy Solutions	<ul><li>Medication reconciliation</li><li>Adherence solutions</li></ul>		
Technology solutions	<ul> <li>Clinical and financial analytics</li> <li>Connected workflows (e.g., Carehub)</li> </ul>		

Customization to local markets and members enables value-based care growth, improved outcomes and care experience, and drives efficiency across a number of metrics +16% >\$4B +21% +19% >1M HEDIS scores<sup>2</sup> **Proportion of MAPD** NPS<sup>2</sup> Add'I days at home Incremental members in value for HCCP members<sup>3</sup> savings<sup>4</sup>

based care arrangements<sup>1</sup>

28

Targeted initiatives and infrastructure investments are creating continued improvements in quality indicators

Sample quality initiatives and infrastructure investments

**Process reengineering** 


**Data and analytics** 

**Technology infrastructure** 


Organizational structure and alignment



# Proactively identifying and engaging at-risk members is improving quality and outcomes



Integrating our capabilities and customizing them to local markets creates a winning value proposition and sustains long-term growth



Range of provider integration models ... ... Supported by locally-delivered clinical and population-health capabilities ... ... Helps deliver improved health outcomes at lower cost ...

... Enabling competitive products to win in the market

## Provider


**Roy Beveridge, MD** Chief Medical Officer

**Joe Jasser, MD** President, Care Delivery



#### Investor Day 2017

Our Integrated Care Delivery model provides a platform of capabilities to thrive in the future environment



Demonstrated success of integrated care, population health




Build provider partnerships through continued advancement of fully integrated care



Enhance member growth through differentiated offering

Humana has been evolving toward a system of care that truly integrates provider and health plan activity



Time

Our success across primary care models is built on delivering and integrating a diverse set of clinical programs and analytics



### **Care delivery and services**

We have proven success and continued growth managing a variety of primary care models in a variety of markets

	Increasing risk-sharing MSO platform can be deployed across all models						
	Engaged physicians	Path to value	Alliances	JVs	Full-risk partners	Owned clinics	
Example Humana partners or assets	<b>∡</b> Transcend <sub>™</sub>	Various partners	iorahealth JSA Davita. Medical Group OAK STREET HEALTH	+JenCare	Medical Group	Partners in Primary Care. CAC <sup>®</sup> FLORIDA Medical Centers	
MER <sup>1</sup>	87.6%	86.2%	86.0% <sup>2</sup>	84.3%	84.1%	81.8%	

We see better performance with increased risk-sharing

# We vary our deployment based on local market dynamics



# Improving performance of South Florida owned clinics

#### More contemporary look and experience:

- Investment to revamp and modernize clinics
- New format and experience to cater to preferences of younger seniors

### Optimizing center footprint:

- Optimize center locations
- Rationalization and consolidation of clinics to meet market needs



Sustainable platform to enable Medicare strategy in FL

# Driving physician engagement and retention:

- Fostering physician-led culture of clinical excellence
- Revamping operating model to better align incentives

### Drive toward a consistent, scalable platform:

- Adoption of uniform EMR technology platform
- Establishment of consistent best practice clinical care and documentation protocols
- Staffing ratio optimization

Evolving engagement with Baton Rouge Clinic demonstrates how provider partnerships can improve outcomes



#### Background

- Prestigious, physician-owned, multispecialty clinic
- Treats significant portion of Humana MA members
- Strong relationship built over many years, despite initial resistance to MA


#### **Keys to success**

#### **Collaborative relationship built on open communication and trust**

- Piloted numerous initiatives
- Active Bold Goal partner

#### Strong physician alignment to drive patient outcomes:

- CaDET liaison with physician education sessions<sup>1</sup>
- Embedded nurse in clinic
- Weekly meetings with Provider Engagement Executive



# PiPC delivers clinical benefits to members through improved care management and coordination

In 2016, we launched our first four fully-owned de novo primary clinics outside of Florida





Greenville, SC



#### Advancing our strategy

Deployed PiPC<sup>1</sup> & Transcend MSO, moved ~13k additional Humana members into value-based reimbursement relationships in past six months



**Clinics integrated with Healthcare** Services segment, leveraging onsite retail pharmacy, Humana At Home, and Humana Behavioral Health care management



**Clinical model supports simplified** experience

- **Onsite services**
- Data interoperability through common EMR<sup>2</sup> platform and Integrated referral scheduling

# Q&A

# Humana

Investor Day 2017

# Evolving Clinical Model

# William Fleming, PharmD


President, Healthcare Services

**Chris Kay** Chief Innovation Officer



#### Investor Day 2017

Our Integrated Care Delivery model provides a platform of capabilities to thrive in the future environment





Building on established care coordination capabilities



Expanding clinical care delivery capabilities

Investing in improved engagement with individual members and providers to slow disease progression


# Our clinical platform creates deeper integration at key moments of influence

Prevention	Primary	Pharmacy	Home	Behavioral
& wellness	care		health	health
<b>9365</b>	Partners in	Humana	<b>Humana</b>	Humana
	Primary Care.	Pharmacy Solutions.	At Home <sub>™</sub>	Behavioral Health.



# Humana Pharmacy Solutions has demonstrated success, path forward to future growth

We are the nation's 4th largest PBM by Rx volume and manage \$26B drug spend



# Our pharmacy operations have national scope and expanding presence

#### Established asset base<sup>3</sup>

- 800 in-house pharmacists; 1,700 technicians
- 7 call centers with 2,000 staff
- 2 fulfillment centers with 1,500 support staff

#### Planned expansion in mail order, retail pharmacy

- 2 new dispensing sites: 1 mail and 1 Specialty
- 35 retail in-clinic pharmacies
- 10 new in-clinic pharmacies planned for 2017

In-clinic pharmacists have 90+% clinical engagement with members needing medication reviews

# Our care management programs engage more than 1 million members annually



Care in Home

**10,000** Care Managers and **3,000** Nurse Practitioners (NP)<sup>1</sup>

>1 million engaged chronic care members<sup>1</sup>

Current performance

>215,000 in home assessments projected in 2017

>1 million more days at home since 2013

>\$650M spend on home health annually



Employ 200+ clinicians 70,000 providers in network


**50 owned and affiliated clinics offer** integrated behavioral health services

6 million TRICARE beneficiaries will begin service in 2018


Outcomes

48% reduction in APTs<sup>1,2</sup>; leveraging analytics to optimize clinical interventions 23% improvement in utilization management with integrated medical and behavioral care<sup>3</sup>

# At each stage of maturity, our programs become more sophisticated and deliver incremental value




We are driving two key advances in our clinical model to unlock additional value at key moments of influence




Strategy is inherently local; integration increases ability to impact moments of influence with members

We are building our capabilities around a deeper understanding of our members' health and how their conditions impact cost




There are many lifestyle and care delivery barriers that stand between members and their best health



### **Chronic Disease Progression**

These barriers lead to significant value loss which can be reversed by better integration and more robust clinical capabilities



With a more holistic clinical model, we will be able to break down barriers to good health and reduce costs

#### Humana. 1. Annualized costs of disease progression projected from 2014 membership cohort

Clinical model in action: Facilitating important conversations between consumers and providers at key moments of influence



**Post Discharge Medication Reconciliation** 



Nurse visits home post discharge

Clinical Pharmacist teleconsult *Complete, accurate shared Med List and recommendations*  Physician and Dispensing Pharmacy Follow up

# Our medication reconciliation solution drives significant impact

#### **Key Components**

**Collaborative Care Team** Including Nurse Care Manager and Clinical Pharmacist

Integrated Information and Insights Connected to claims data and updated in realtime

**Connected Workflow Tools** Purpose-built tools support collaboration and in-home connected experience

Clear Call to Action at Moment That Matters Clear recommendations shared with care team

#### Impact<sup>1</sup>

**73%** of Members had issues that required high value Pharmacist counseling

**98%** of Pharmacist consults were seen as helpful and valuable by Care Managers

**1.8%** reduction<sup>2</sup> in 30-day readmission rate for members with Pharmacist consult

**94%** of MTM<sup>3</sup>-eligible Members received STARS CMR<sup>4</sup> consult


# Simplified Experience

Jody Bilney Chief Consumer Officer Brian LeClaire, Ph.D. Chief Information Officer




### **Investor Day 2017**

Our Integrated Care Delivery model provides a platform of capabilities to thrive in the future environment




# We have a suite of proven capabilities on which to deliver our strategy




#### **Umana** 1. This statistic and all others on this page refer to 2016.

We will enable the transition to holistic health by removing friction points through process and technology innovation




Constituency-centric



# Prospective

Information flow is bi-directional Consumer-centric

We are focused on the areas of greatest leverage – the intersections of consumer and provider experience



Addressing these problems is a key to our growth

Human-centered design informs technological capabilities to deliver simplified experience


# **Human-Centered Design**

- Start with consumer/provider needs
- Conduct empirical, fieldresearch based approach
- Map experience
- Redesign frictionless processes and experiences that build relationships

# Leveraging technology

- Mobile first
- Social-based
- Cloud
- Analytics
- Omni-channel
- Common care plan

We have proven experience creating integrated technological tools to drive improved outcomes and lower costs



Simplified experience in action: Reducing shared friction points and improving outcomes by innovating the process




**Specialist Referral and Scheduling Assistance** 



PCP practice uses tool to choose high-value specialist Appointment scheduled before patient leaves office Specialist closes loop on appointment with referring PCP

# Friction points abound throughout the system; solving them will unlock tremendous value in care experience and productivity



Referrals are just one opportunity of many, including care coordination, administration, compliance, and other areas

### Humana.

1. CMS 2015, Health Affairs 2010, Kyruus 2014; all dollar values in terms of estimated annual healthcare spend 2. CMS 2015, Health Affairs 2010, Becker's Hospital Review 2015 3. Pittsburgh Post-Gazette 2013 4. NEHI 2010 5. CMS 2015, Healthcare Finance Management Association (HFMA) 2016, New England Journal of Medicine (NEJM) 2014 6. Health Affairs 2014

# Q&A

# Humana

Investor Day 2017


# Group

**Beth Bierbower** President, Group and Specialty



### **Investor Day 2017**

# Group provides strategic advantages to Humana



# Differentiated strategy is delivering results

	Growth in the "Sweet Spot"	% Members in Sweet Spot		
Differentiated value proposition in the "Sweet Spot"	<ul> <li>Value proposition – Leading with health, leveraging incentives, wellness programs based on behavioral economics and actuarial science</li> <li>Customer Segmentation – Targeting the "Sweet Spot" under 1,000 lives for medical coverage</li> </ul>	50%	60% 65% 2015 2016	
		-		
	Driving member engagement	go365 participation		
Delivering significant value to customers	<b>97%</b> increase in <b>\$47.5M</b> cumulative groups receiving premium credits	15%	21% 24%	
	wellness credits <sup>1</sup> given 2014-2016	2014	2015 2016	
	Improving financial performance	Group pretax margin		
Delivering financial	Pretax margin improvement through cost		4.3% 4.7%	
performance to	reductions and disciplined pricing:	2.8%		
Humana	<ul> <li>Transformed distribution channel</li> <li>Flattened leadership infrastructure</li> <li>Leveraged technology to drive efficiency</li> </ul>	2014	2015 2016	

Group advances Humana's corporate strategy by partnering with members as they age and delivering integrated care

Group helps fulfill mission to be a partner for life by serving Medicare age-ins Drives benefits to members through integrated care<sup>1</sup>

Medicare member 20K Conversion from Group age-ins, 2014-2016

550K+

Prescriptions filled for Group members

**42K+** Group participants in Humana clinical programs

**Proactive outreach** to Group members leveraging our consumer infrastructure and sales channels has driven **incremental MA growth** 


100%

Group participants with access to Humana Behavioral Health

# **TRICARE:** Recent successes



Largest Medical Services contractor to the Defense Health Agency 6 million covered lives by January 1, 2018 \$40B in medical spend by the Department of Defense



#### **Priorities**

T2017 East Region Transition currently on track for start of healthcare delivery January 1, 2018, including provider network

FY2017 NDAA<sup>1</sup> provisions underway for January 1, 2018

# Financial Update

**Brian Kane** Chief Financial Officer



### **Investor Day 2017**

# Strong start to 2017

- 1Q17 EPS of \$7.49 GAAP/\$2.75 Adjusted<sup>1</sup> and consolidated revenues of \$13.8 billion GAAP/\$13.5 billion Adjusted<sup>1</sup> primarily driven by:
  - Outperformance in the Retail segment, largely attributable to prior period development in the company's individual Medicare Advantage business
  - All of the company's businesses performing well and early indicators are positive relative to management's initial expectations around medical utilization
- Full-year 2017 EPS guidance raised to at least \$16.91 GAAP/at least \$11.10 Adjusted<sup>1</sup>, primarily driven by same items impacting 1Q17 results
- Detailed 1Q17 results and detailed components of 2017 full-year earnings guidance to be provided May 3, 2017

# **Considerations for 2018**

### General

- Constraints resulting from the terminated merger agreement behind us
- Continue to take enterprise-wide view balancing margin and membership growth


### Medicare rates/Other bid considerations

- Final Rate Notice for 2018 expected to result in 0.45 percent<sup>1</sup> rate increase for Humana versus CMS' estimate for the sector of approximately 0.85 percent<sup>1</sup> on a comparable basis; difference for Humana primarily due to the impact of FFS county rebasing
- Ensuring we meet customary CMS requirements for contract entities for 2018
- Assuming current law for the Health Insurer Fee (HIF); i.e., HIF returns in 2018
- Early 2017 outperformance to be given consideration in the bids
- On-going optimization of clinical programs

### Membership

- Individual Medicare Advantage membership growth expected to accelerate
- Expect to maintain leading growth position in individual Medicare stand-alone PDP

## Focus on administrative costs



All periods presented are adjusted, as applicable, to exclude the individual commercial medical business, the health insurer fee, transaction costs associated with the terminated merger agreement, Concentra Inc. operating results, and guarantee fund assessment expense to support policyholder obligations of Penn Treaty (an unaffiliated long-term care insurance company).

### \$1 Billion Savings

The **reduction** in the adjusted operating cost ratio from **13.0% in 2013** to **11.2% in 2017** equates to an **operating cost savings** of approximately **\$1 billion** based upon 2017E premiums & services revenues.

#### **Categories of administrative cost reductions**

- Reevaluation of staffing metrics based on area workflows
- Print & Postage
- Travel and Entertainment
- Procurement savings
- Facilities consolidation

#### **Process Transformation Office**

- Delve deeper into the underlying processes that drive results
- Provide teams cross-functional process views to highlight enterprise-wide opportunities
- Process excellence goals to drive:
  - ✓ Better productivity/lower costs
  - Enhanced consumer experience
  - ✓ Reduced operational risk
  - Cross-functional knowledge building for associates

## Annual parent cash generation (illustrative only)

(\$ millions, all numbers are approximations)

Major sources		Capital needs
Annual <b>Statutory Dividend</b> Capacity <b>Unregulated</b> After-Tax Earnings <sup>1</sup> <b>Parent Company Sources</b>	\$900 to \$1,200 700 to 800 <b>\$1,600 to \$2,000</b>	<ul> <li>Organic growth – generally 10% to 12% of premium growth</li> </ul>
Less		<ul> <li>Return cash to shareholders</li> <li>Strategic acquisitions/investments</li> </ul>
Major uses		
Parent Company Capital Expenditures <sup>2</sup> Shareholder Dividends <sup>3</sup> Tax-Effected Interest Expense <sup>4</sup> Parent Company Uses	\$400 to \$450 240 140 <b>\$780 to \$830</b>	
=		Annual parent cash generation ~ \$800 to ~ \$1,200 <sup>5</sup>
Available for capital deployment	~\$800 to \$1,200⁵	\$500 to \$1,200

1. Primarily includes Healthcare Services segment earnings. 2. The parent company funds over 70% of consolidated capital expenditures. 3. Reflects annual impact of the current 73 quarterly shareholder dividend of \$0.40 per share. 4. Reflects the annual impact of new debt. 5. Excludes changes in working capital which can vary year to year.

## Parent company cash and short-term investments – 2017E

\*Excludes \$300M existing

\$1,085

commercial paper borrowings.

(\$ millions, all numbers are approximations)

12/31/16 Parent Cash and Short-Term Investments	\$1,700*
Annual Parent Cash Generation (mid-point)	1,000
Minimum Cash Held For Liquidity	(500)
Ordinary Cash Availability – 2017E	\$2,200

Plus

Long term target debt to total capital ratio in the range of 30-35% to maintain investment grade credit rating

	•••
2017 Additional sources	
Bond Offering Proceeds	\$990
Net Merger Agreement Termination Proceeds	630
Net Sources of Cash	\$1,620
=	
Available for Capital Deployment in 2017	\$3,820
Less	
2017 Additional uses	
Accelerated Stock Repurchase Initiated 1Q17 <sup>1</sup>	\$1,500
Stock Repurchases Remainder of 2017 <sup>1</sup>	500
Closed-Block Long-Term Care Capital Contribution	535
Capital to Support Growth	200
Net Uses of Cash	\$2,735

**December 2017E Parent Cash and Short-Term Investments (Excludes Commercial Paper)** 

Available M&A capacity				
Debt to total capital	New debt raise <sup>2</sup>		Estimated available cash	
35%	\$1,100	\$1,100	\$2,200	
40%	\$2,500	\$1,100	\$3,600	

Strategic Focus
<ul> <li>Home health</li> </ul>
Primary care
<ul> <li>Simplified experience</li> </ul>
<ul> <li>Behavioral health</li> </ul>

In-clinic retail pharmacy

1. Repurchases under the \$2.25 billion share repurchase program approved by the Board of Directors in February 2017.

Humana 2. Debt to total capital and corresponding new debt raise assumed as of 12/31/2017 for strategic acquisitions/capital investment. Balanced approach of Integrated Care Delivery model drives superior long-term earnings

## Low to mid teens Adjusted EPS growth

High value integrated care delivery creates a virtuous cycle of growth



#### Key Drivers of Long-Term Adjusted EPS Growth

- Maintain disciplined pricing while focusing on the lifetime value of members
  - At or above market Individual Medicare Advantage membership growth
  - Individual Medicare Advantage margin target of 4.5%-5.0% long-term
- Retain leading individual stand-alone PDP position
- Continue pharmacy and other healthcare services growth in excess of individual Medicare Advantage and PDP membership growth
- Drive strong ROIC in commercial group business
- Increase productivity/lower administrative costs
- Pursue M&A opportunistically to advance strategy
- Return of capital

## Q&A

# Humana

Investor Day 2017

## GAAP to Non-GAAP

**Investor Day** New York, NY

# Humana

April 25, 2017

## Reconciliations of GAAP to non-GAAP financial measures

Diluted earnings per common share (EPS)	2014	2015	2016	2017E
				At least
Generally Accepted Accounting Principles (GAAP)	\$7.36	\$8.44	\$4.07	\$16.91
Adjustments (described below)	0.93	0.96	6.85	~(5.81)
				At least
Adjusted (non-GAAP) – recast as needed*	\$8.29	\$9.40	\$10.92	\$11.10

2017E Adjusted results exclude the following operating (income) losses or expenses:

- ~\$0.15 per diluted common share of projected operating losses for the company's individual commercial medical (Individual Commercial) business given the company's planned exit on January 1, 2018.
- (~\$4.36) per diluted common share of net gain associated with termination of the merger agreement.
- ~\$0.31 per diluted common share of amortization expense associated with identifiable intangibles.
- (~\$2.15) per diluted common share for the beneficial effect of a lower effective tax rate in light of pricing and benefit design assumptions
  associated with the 2017 temporary suspension of the non-deductible health insurance industry fee; excludes portion applicable to the
  company's Individual Commercial business.
- ~\$0.24 per diluted common share of guaranty fund assessment expense to support the policyholder obligations of Penn Treaty (an unaffiliated long-term care insurance company).

#### 2016 Adjusted results exclude the following losses or expenses:

- \$3.78 per diluted common share of operating losses for the company's Individual Commercial business given the company's planned exit on January 1, 2018, including the write-off of receivables associated with the risk corridor premium stabilization program.
- \$0.64 per diluted common share of transaction and integration costs for the then-pending transaction.
- \$0.32 per diluted common share of amortization expense associated with identifiable intangibles.
- \$2.11 per diluted common share of reserve strengthening related to the company's non-strategic closed block of long-term care insurance business.

\* Beginning with its first quarter 2016 results, the company has been adjusting for the exclusion of amortization of identifiable intangibles to align with reporting methods used across the managed care sector. Additionally, in the first quarter of 2017 the company announced it would be exiting the Individual Company announced it would be exiting the Individual Company and the Individual Company announced it would be exiting the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company and the Individual Company announced it would be exited and the Individual Company and the Individual Company announced it would be exited and the Individual Company announced it would be exited and the Individual Company and the Individual Company announced announced announced announced announced

# Reconciliation of GAAP to non-GAAP financial measures

2015 Adjusted results exclude the following (income) losses or expenses :

- \$2.00 per diluted common share of operating losses for the company's Individual Commercial business given the company's planned exit on January 1, 2018; includes impact of premium deficiency reserve related to the company's 2016 ACA-compliant Individual Commercial offerings.
- \$0.14 per diluted common share of transaction and integration costs for the then-pending transaction.
- \$0.39 per diluted common share of amortization expense associated with identifiable intangibles.
- (\$1.57) per diluted common share of gain associated with the company's sale of its wholly-owned subsidiary, Concentra Inc. on June 1, 2015.

2014 Adjusted results exclude the following operating losses or expenses:

- \$0.29 per diluted common share of operating losses for the company's Individual Commercial business given the company's planned exit on January 1, 2018.
- \$0.49 per diluted common share of amortization expense associated with identifiable intangibles.
- \$0.15 per diluted common share of expenses associated with early retirement of debt.

# Reconciliations of GAAP to non-GAAP financial measures *continued*

EPS	1Q17
GAAP	\$7.49
Adjustments (described below)	(4.74)
Adjusted (non-GAAP)	\$2.75

1Q17 Adjusted results exclude the following operating (income) losses or expenses:

- (\$0.27) per diluted common share of projected operating income for the company's Individual Commercial business given the company's planned exit on January 1, 2018.
- (\$4.26) per diluted common share of net gain associated with termination of the merger agreement.
- \$0.08 per diluted common share of amortization expense associated with identifiable intangibles.
- (\$0.52) per diluted common share for the beneficial effect of a lower effective tax rate in light of pricing and benefit design assumptions associated with the 2017 temporary suspension of the non-deductible health insurance industry fee; excludes portion applicable to the company's Individual Commercial business.
- \$0.23 per diluted common share of guaranty fund assessment expense to support the policyholder obligations of Penn Treaty (an unaffiliated long-term care insurance company).

# Reconciliations of GAAP to non-GAAP financial measures *continued*

Consolidated revenues (in millions)	1Q17
GAAP	\$13,762
Revenues associated with the individual commercial business (a)	(283)
Adjusted (non-GAAP)	\$13,479

<u>1Q17 Adjusted consolidated revenues exclude the following:</u>

a) Results associated with the company's Individual Commercial business given the company's planned exit on January 1, 2018.

# Reconciliation of GAAP to non-GAAP financial measures

#### continued

Operating cost ratio	2013	2014	2015	2016	2017E
GAAP	15.5%	15.9%	13.6%	13.5%	~11.5%
Results associated with the Individual Commercial business (a)	(0.4%)	(0.4%)	(0.4%)	(0.5%)	~(0.2%)
Results associated with Concentra Inc.(b)	(2.1%)	(1.8%)	(0.8%)	-	-
Expenses associated with the terminated merger agreement (c)	-	-	-	(0.2%)	-
Health insurance industry fee (d)	-	(1.1%)	(1.5%)	(1.6%)	-
Guaranty fund assessment expense (e)	-	_	-	-	~(0.1%)
Adjusted (non-GAAP) – recast as needed*	13.0%	12.6%	10.9%	11.2%	~11.2%

Adjusted results exclude the following:

- a) Results associated with the company's Individual Commercial business given the company's planned exit on January 1, 2018, including the write-off of receivables associated with the risk corridor premium stabilization program in 2016.
- b) Results associated with Concentra Inc., the company's previously wholly-owned subsidiary that was sold in June 2015.
- c) Expenses associated with the terminated merger agreement.
- d) The non-deductible health insurance industry fee (excluding the Individual Commercial business impact).
- e) Guaranty fund assessment expense to support policyholder obligations of Penn Treaty (an unaffiliated long-term care insurance company).

\* Beginning with its first quarter 2016 results, the company has been adjusting for the exclusion of amortization of identifiable intangibles to align with reporting methods used across the managed care sector. Additionally, in the first quarter of 2017 the company announced it would be exiting


## Bios

**Investor Day** New York, NY

# Humana

April 25, 2017

## Bruce Broussard President and Chief Executive Officer



Bruce Broussard, President and CEO, joined Humana in 2011. Under his leadership, Humana has created an integrated care delivery model centered on improving health outcomes, driving lower costs, enhancing quality, and providing a simple and personalized member experience. With its holistic approach, Humana is dedicated to improving the health of the communities it serves by making it easy for people to achieve their best health.

Bruce brings to Humana a wide range of executive leadership experience in publicly traded and private organizations within a variety of healthcare sectors, including oncology, pharmaceuticals, assisted living/senior housing, home care, physician practice management, surgical centers and dental networks.

Prior to joining Humana, Bruce was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Bruce served in a number of senior executive roles, including Chief Financial Officer, President, Chief Executive Officer and Chairman of the Board.

Bruce plays a leadership role in key business advocacy organizations such as the Business Roundtable, the American Heart Association CEO Roundtable, and The Aspen Group. He is also a member of the Board of Directors of KeyCorp.

## Roy Beveridge, MD Senior Vice President and Chief Medical Officer



Dr. Roy Beveridge joined Humana in 2013 as Senior Vice President and Chief Medical Officer. He is responsible for developing and implementing Humana's clinical strategy, with an emphasis on advancing the company's integrated care delivery model.

Dr. Beveridge is known for creating collaborative environments among physician communities and providing thought leadership around population health. He is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard.

Previously, Dr. Beveridge served as Chief Medical Officer for McKesson Specialty Health. Prior to McKesson's acquisition of US Oncology in 2010, he served as the Executive Vice President and Medical Director at US Oncology. He has published extensively in the fields of medical oncology, stem cell transplantation, quality design and population health.

Dr. Beveridge earned a Bachelor of Arts degree from Johns Hopkins University and a medical degree from Cornell University Medical College. He completed his residency in internal medicine at University of Chicago Hospitals and his fellowship at Johns Hopkins Hospital.

Board certified in medical oncology and internal medicine, Dr. Beveridge has authored more than two hundred articles on a wide range of medical topics such as hematology, stem cell transplantation and quality standardization, and population health/value-based medicine.

Dr. Beveridge is a member of the American Medical Association, American Society of Clinical Oncology (ASCO) and the American Society of Hematology. He has served on many boards related to medical oncology and patient advocacy.

## Beth Bierbower President, Group and Specialty



Beth Bierbower is President, Group and Specialty Segment for Humana. She is responsible for driving the growth and profitability of Humana's Employer Group products including medical, specialty and wellness offerings. Under Beth's leadership, the segment is focused on driving health engagement to small to mid size organizations. Beth is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard.

In addition, Beth is responsible for Humana's Government Business, which is the largest Medical Services contractor providing service to active duty and retired military and their eligible family members through a contract with the Defense Health Agency.

In her prior role, Beth led Humana's Specialty Benefits area, including dental, vision, life, disability, and workplace voluntary benefits. Beth started her career at Humana in 2001. As Product Innovation Leader, she drove the consumer strategy that included development of new products and services that helped position Humana as a leader in consumerism.

Beth has published a book titled *Engage! A Guide to Involving Your Consumers in their Health*. Beth is a frequent speaker and has served as chair of a number of industry conferences. She is a frequent contributor to LinkedIn.

She earned a master's in public management, graduating with highest honors, from Carnegie Mellon University.

## Jody Bilney Senior Vice President and Chief Consumer Officer



Jody Bilney is Senior Vice President and Chief Consumer Officer for Humana. With responsibility for marketing, brand development, the consumer experience, digital, consumer data and analytics and corporate reputation enhancement, Jody plays a leading role in the organization's ongoing transformation into a consumer-driven enterprise. She is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard.

Before joining Humana in 2013, Jody served as Executive Vice President and Chief Brand Officer for Bloomin' Brands, Inc., a Tampa-based upscale-casual restaurant company with Outback Steakhouse as its flagship chain. There she headed brand/business strategy, R&D, marketing, corporate communications and business development across the enterprise. She was also a key member of the executive team that positioned the company for a successful Initial Public Offering (IPO) in August, 2012.

Prior to Bloomin' Brands, Jody held senior executive positions at Charles Schwab and Verizon, where she led consumer-focused brand-transformation initiatives. She is a member of the Board of Directors for Masonite, Inc. and for Up2US, a national leader in sports-based youth development.

A Michigan native, Jody earned a Bachelor of Science degree in Economics, with a minor in Marketing, from Clemson University in Clemson, S.C.

## William Fleming, PharmD President, Healthcare Services



Dr. William Fleming is President - Healthcare Services, where he is responsible for Humana's clinical and pharmacy businesses that service all Humana segments. William is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard.

A 23-year Humana veteran, William has spent the majority of his career pioneering Humana's pharmacy business and bringing forward a clinical integration belief to drive a total cost-of-care view of the world.

In 2017, William has expanded his leadership to include a focus in Humana's home business, behavioral health business, clinical care businesses, and advanced clinical analytics. William has a passion for using an entrepreneurial spirit in simplifying healthcare, providing value for consumers (both the patient and the physician), and developing high performing teams that share the common goal of improving health outcomes and clinical quality.

William received his BS Pharmacy from the University Of Kentucky College Of Pharmacy; where he went on to receive his Doctor of Pharmacy (PharmD). He also holds a BA in General Studies from Transylvania University with an emphasis in biology and economics. William currently serves as Chairman of the Board of Directors of PCMA (the Pharmaceutical Care Management Association) and has held prior Board/Trustee appointments to various pharmacy and charity organizations. William has also been named a Fellow in the Academy of Managed Care Pharmacy (FAMCP).

## Chris Hunter Senior Vice President and Chief Strategy Officer



Chris Hunter is Senior Vice President and Chief Strategy Officer at Humana, where he is responsible for leading Humana's corporate strategy planning process, as well as setting the direction of the company's merger and acquisition and joint venture activities. In his role Chris partners closely with business leaders to ensure the corporate strategy is aligned across the organization and is actionable. He is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard.

Chris has extensive executive experience with both public and private growth companies and brings broad knowledge of the healthcare industry to his role. His experience ranges from leadership of strategic planning and corporate development to responsibilities that included broad P&L and Board of Directors accountability.

Chris was most recently President of Provider Markets at TriZetto, a Denver-based health IT software/services firm serving more than 200,000 providers. He helped take the company private in 2008. Previously, Chris served on the executive leadership team at BlueCross BlueShield of Tennessee as Senior Vice President of Emerging Markets, where he was responsible for full P&L and management of the company's wholly-owned subsidiaries and equity investments. While at BlueCross BlueShield of Tennessee, he was simultaneously President and CEO of Onlife Health, their national health and wellness subsidiary.

Chris earned a bachelor's degree with highest honors from the University of North Carolina at Chapel Hill and has an MBA from Harvard Business School. He currently serves on the Board of the Honors Program at the University of North Carolina.

## Tim Huval Senior Vice President and Chief Human Resources Officer



Tim Huval joined Humana as Senior Vice President and Chief Human Resources Officer, where he leads all aspects of human resources, including talent acquisition, inclusion and diversity, learning, succession management, engagement, compensation and benefits, health and well-being, enterprise solutions, and business services – procurement, facilities, real estate, and safety and security. Tim is a member of the Management Team, which sets the firm's strategic direction, and reports to the President and Chief Executive Officer Bruce Broussard.

Prior to joining Humana, Tim spent 10 years at Bank of America in multiple senior-level roles, including Human Resources executive and Chief Information Officer for Global Wealth & Investment Management, as well as Human Resources executive for both Global Treasury Services and Technology & Global Operations. Additionally, he led several large operations organizations, including Global Card Services, where he was responsible for all card operations and customer service, serving more than 40 million customers. Tim also held numerous leadership roles in operations and Human Resources at Gateway Inc.

While at Bank of America, Tim served as chair of the Consumer Banking, Business Banking and Enterprise Client Coverage Diversity & Inclusion Business Council, responsible for promoting an inclusive work environment. He also served as the executive sponsor of the Military Support & Assistance Group which supports efforts to attract, integrate, retain and develop military veterans.

Tim serves on the board of directors of Seacoast Banking Corporation, which provides banking and investment services to businesses and consumers along Florida's east coast and central region. He has also contributed to various non-profit boards, including Family and Children's Place in Louisville, Delaware United Way, Delaware Children's Museum, United Way of the Virginia Peninsula, Hampton Roads Chamber of Commerce, Hampton Roads Technology Council, Peninsula Alliance for Economic Development, Utah Information Technology Association, and Youth Homes, Charlotte, N.C.

Tim earned a master's degree in public administration from Brigham Young University, a bachelor's degree in marketing from Weber State and an associate degree in business management from Salt Lake Community College. He was also awarded an honorary doctorate in Humane Letters from Salt Lake Community College.

## Joe Jasser, MD President, Care Delivery



Dr. Joseph Jasser joined Humana in January 2017 as President, Integrated Care Delivery. He is responsible for the clinical operations of Humana's wholly owned clinics, its JV partnerships, and the company's Transcend MSO. His focus is on the growth and development of the delivery of care across the Humana markets. Dr. Jasser is known for operational and strategic development of care models with emphasis on creating collaborative and engaging environments for physicians. He is a member of the Management Team, which sets the firm's strategic direction, and reports to the President and Chief Executive Officer Bruce Broussard.

Prior to joining Humana, Dr. Jasser was the President and CEO of Dignity Health Medical Foundation. In his role at Dignity, Dr. Jasser had the direct oversight of more than 125 ambulatory clinics throughout California, with more than 4,000 staff and 800 physicians. He had operational and fiduciary responsibility for more than \$1.7B in gross patient revenue and more than 2M patient visits annually.

Prior to joining Dignity Health, Dr. Jasser was the VP of Operations and Chief Medical Officer of Cigna/HealthSpring Point of Care Clinics. In addition to this role within Cigna, Dr. Jasser was the Senior Medical Director for Cigna Medical Group. Prior to Cigna, Dr. Jasser was the Regional Medical Director for Concentra in Houston, TX.

Dr. Jasser obtained his BS in Biochemistry, *summa cum laude* from The Ohio State University, his medical degree from The Ohio State University College of Medicine and his Executive MBA from Washington State University. He completed his residency in Internal Medicine at Summa Health System in Akron, OH. He is board certified in Internal Medicine by the American Board of Internal Medicine.

## Brian Kane Senior Vice President and Chief Financial Officer



Brian Kane is Humana's Senior Vice President and Chief Financial Officer, with responsibility for all accounting, actuarial, analytical, financial, internal audit, investor relations, tax and treasury activities. He is a member of the Management Team, which sets the strategic direction for the company.

Brian joined Humana after spending nearly 17 years at Goldman, Sachs & Co., where he held a number of leadership roles and was responsible for driving client relationships and leading strategic and financing transactions for a number of companies across multiple industries. He also served as the lead financial advisor on many of the managed care industry's most important strategic transactions.

Brian holds an MBA from Harvard University and a Bachelor of Arts degree, with distinction, in Economics and Political Science from Stanford University.

## Chris Kay Senior Vice President and Chief Innovation Officer



Chris Kay is Senior Vice President and Chief Innovation Officer at Humana. In this role, he works closely with internal business leaders, as well as outside partners, to design, test, and operationalize game-changing innovations. He is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard.

Chris is a keen innovator with a passion for creating new businesses in large global organizations and for launching products and services that enhance the consumer experience. He most recently served as Managing Director and CEO of Citi Ventures, Citigroup's global corporate venturing arm. At Citi Ventures, he pioneered efforts to simplify and improve the banking experience for Citi's millions of customers through use of digital, mobile, data, and other customer-centric solutions. Chris and his team also invested in and worked closely with a portfolio of companies to accelerate time-to-market of new capabilities at Citi.

Prior to joining Citi in 2007, Chris held several leadership positions at Target over a 12-year period, ranging from leader of large merchandising departments to store operations and property development.

Chris holds a J.D., magna cum laude, from the University of Minnesota and a B.A. in French and Economics from the University of Wisconsin-Madison.

## Brian LeClaire, PhD Senior Vice President and Chief Information Officer



Brian LeClaire serves as Humana's Senior Vice President and Chief Information Officer. He is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard. In his role, Brian leads the company's information technology organization, responsible for setting its technology vision and delivering all technology services, including analytics, mobile and legacy development, as well as infrastructure management. Brian has transformed the information technology organization, gaining efficiencies while positioning Humana for explosive growth on its journey of helping people achieve life- long well-being.

A nationally-recognized technology executive, Brian has received accolades for his exceptional technology leadership and innovative approach to business and IT partnership. In 2005, he was named to *ComputerWorld's* Premier 100 IT Leaders, and in 2012, he was named one of *Insurance* & *Technology Magazine's* Elite 8 for leveraging the power of advanced analytics and big data to improve healthcare outcomes.

Brian holds a Ph.D. from Oklahoma State University in Management Information Systems, an MBA from the University of Wisconsin and a BA from Ripon College.

## Heidi Margulis Senior Vice President, Corporate Affairs



As Senior Vice President, Corporate Affairs, Heidi Margulis leads strategy development and execution for Humana's state and federal government relations, advocacy and public policy initiatives, including strategic alliance relationships in national and key local markets. In concert with those responsibilities, she guides the company's community engagement and corporate social responsibility initiatives as well as has administrative oversight of the Humana Foundation. Ms. Margulis is a member of the Management Team which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard. Heidi joined Humana in 1985 and has held increasing responsibilities for regulatory and legislative public affairs as well as for external affairs initiatives. She was promoted to Vice President, Government Affairs in 1995, Senior Vice President Government Affairs in 2000, Senior Vice President, Public Affairs in 2003 and her current position in December 2014.

Two U.S. Secretaries of Health & Human Services recognized Heidi's federal government health program expertise with appointments to Secretary Tommy Thompson's Advisory Committee on Regulatory Reform and Secretary Donna Shalala's Advisory Panel on Medicare Education.

Heidi serves on the board of the Humana Foundation, on Kentucky Workforce Innovation Board's executive committee as well as the board, and on the executive committee and board of the Kentucky Authority for Educational Television. She formerly served as vice-chair of the board of the Washington, DC-based Campaign to End Obesity, as board co-chair of Green Ribbon Health (a Medicare Health Support pilot program), chair of the Coordinating Committee of the Health & Retirement Task Force of the Business Roundtable, and serves on several committees of America's Health Insurance Plans. She has served on a variety of local, state, and national civic, charitable, and public-sector boards.

Heidi holds a bachelor's degree in international studies from the University of Louisville.

## Regina Nethery Vice President, Investor Relations



Regina Nethery, Vice President of Investor Relations, is Humana's primary liaison with Wall Street analysts, shareholders and potential investors. Regina also has responsibility for financial messaging to the investor community, including financial press releases, quarterly earnings conference calls, and investor presentations.

Before joining the Investor Relations Department in 2000, Regina led Humana's Internal Audit Department, where she was responsible for directing audits of the company's operational and financial processes. Prior to leading Internal Audit, she was Director of Finance, with responsibility for financial analysis across several of the company's markets.

Regina joined Humana in 1995, having spent the previous ten years with the accounting firm of Coopers & Lybrand (now PricewaterhouseCoopers), where she managed a number of high-profile accounts in both the insurance and health care industries.

Regina is a certified public accountant and a member of the National Investor Relations Institute. She holds a Bachelor of Science in Business Administration degree with a concentration in Accounting from the University of Louisville.


## Christopher Todoroff Senior Vice President and General Counsel



Christopher Todoroff is Humana's Senior Vice President and General Counsel, with responsibility for legal counsel for all aspects of the Company and Corporate Governance oversight, including the Company's Law Department and Compliance function. He is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard. Christopher has served in this position since 2008. Prior to joining Humana, Christopher served as Vice President and Senior Corporate Counsel for Aetna Inc. He was also previously in private practice in New York and Florida.

Christopher holds a J.D., cum laude, from Cornell Law School, where he was an editor of the Cornell Law Review, and a bachelor's degree in business administration from Rutgers University.

## Alan Wheatley President, Retail



Alan Wheatley is the Retail Segment President for Humana. The Retail Segment is comprised of Individual Medicare Advantage, Group Medicare, Medicare Supplement, stand-alone Prescription Drug Plans, Individual Medicaid, and Long-term Support Services. As Segment President, Alan is responsible for leading growth, operational excellence, and profitability across all Retail business lines. He is a member of the Management Team, which sets the firm's strategic direction, and reports to President and Chief Executive Officer Bruce Broussard.

Most recently, Alan was the President of Senior Products, where he directed Humana's Medicare strategy and led Market Operations, Product Development, and the Actuarial Organization. Prior to this, he was Vice President and Chief Financial Officer of Senior Products, where he was responsible for developing the company's Prescription Drug Plan and Medicare Advantage strategy, managing the Senior Products financial position, and leading the Medicare Risk Adjustment organization.

During his more than 25-year career with the company, Alan has served in a number of key leadership roles, including Vice President of Medicare Service Operations and President of the East Region, one of the company's key Medicare geographies. In addition to his career in Medicare, Alan led Humana's internal consulting division. He began his career at Humana in the Finance organization.

Alan has served as Chairman of the Board for the National Senior Olympic Games, and on various non-profit boards. He holds a Master of Business Administration with distinction from the University of Louisville and a bachelor's degree in Finance from the University of Kentucky.